William Blair Issues Positive Forecast for BMY Earnings

Key Points

• William Blair increased their Q3 2025 earnings per share estimate for Bristol Myers Squibb to $1.69, up from $1.68, while the consensus estimate for the current full-year earnings is $6.74 per share.
• Several brokerages have varying ratings on BMY, with one analyst rating it as a Strong Buy, five as Buy, and fifteen as Hold, indicating a generally cautious outlook.
• Bristol Myers Squibb announced a quarterly dividend of $0.62 per share, which translates to a yield of 5.6%, demonstrating its commitment to returning value to shareholders.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Stock analysts at William Blair upped their Q3 2025 earnings per share estimates for Bristol Myers Squibb in a research note issued to investors on Friday, October 10th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $1.69 per share for the quarter, up from their previous forecast of $1.68. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.74 per share. William Blair also issued estimates for Bristol Myers Squibb's FY2025 earnings at $6.48 EPS and FY2026 earnings at $6.28 EPS.

Several other brokerages also recently commented on BMY. Dbs Bank raised shares of Bristol Myers Squibb to a "moderate buy" rating in a research report on Thursday, October 2nd. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Bristol Myers Squibb in a report on Saturday, September 27th. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a report on Thursday, July 31st. Daiwa America lowered shares of Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 5th. Finally, Citigroup lowered their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating on the stock in a research report on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and fifteen have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $57.14.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $44.01 on Monday. Bristol Myers Squibb has a one year low of $42.96 and a one year high of $63.33. The company's 50-day moving average is $46.26 and its 200 day moving average is $47.96. The company has a market capitalization of $89.57 billion, a price-to-earnings ratio of 17.74, a price-to-earnings-growth ratio of 2.26 and a beta of 0.33. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, topping analysts' consensus estimates of $1.07 by $0.39. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The firm had revenue of $12.27 billion for the quarter, compared to analysts' expectations of $11.32 billion. During the same period in the prior year, the firm posted $2.07 earnings per share. The company's quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

Institutional Trading of Bristol Myers Squibb

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank purchased a new stake in shares of Bristol Myers Squibb during the second quarter worth about $1,554,154,000. Wellington Management Group LLP grew its position in shares of Bristol Myers Squibb by 297.0% during the first quarter. Wellington Management Group LLP now owns 23,728,443 shares of the biopharmaceutical company's stock worth $1,447,198,000 after purchasing an additional 17,750,938 shares in the last quarter. GQG Partners LLC grew its position in shares of Bristol Myers Squibb by 22,647.6% during the first quarter. GQG Partners LLC now owns 12,023,454 shares of the biopharmaceutical company's stock worth $733,310,000 after purchasing an additional 11,970,598 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Bristol Myers Squibb during the first quarter worth about $624,369,000. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Bristol Myers Squibb by 16.8% during the second quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company's stock worth $3,277,456,000 after purchasing an additional 10,195,775 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $47.33, for a total value of $2,650,480.00. Following the completion of the sale, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. 0.07% of the stock is currently owned by insiders.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Friday, October 3rd will be given a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. Bristol Myers Squibb's dividend payout ratio is presently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.